## **Special Issue**

# Genomic Analysis of Breast Cancer

## Message from the Guest Editors

Over the past 20 years, advances in genomic analysis of breast cancer have allowed for the constant evolution of clinically relevant subtypes, from

immunohistochemically defined groups to molecular profiles. Advanced comprehensive genomic profiling and multiple targeted therapeutics promoted research on molecular tumor characteristics and led to the development of a new approach for metastatic breast cancer (mBC). Broad implementation of comprehensive genomic profiling across an institution is feasible. During this period, the number of genotype selection trials for breast cancer has steadily increased.

While several independent studies suggest better outcomes for the use of molecularly targeted agents compared to conventional therapies, others did not improve outcomes. These conflicting results highlight one of the major problems in precision oncology: the accurate practical interpretation of biomarkers for patient selection.

This Special Issue focuses on the role of comprehensive genomic profiling in mBC, including both translational and clinical aspects of understanding them to find a potential strategy for breast cancer.

#### **Guest Editors**

Dr. Hiroshi Tada

Department of Breast and Endocrine Surgical Oncology, Graduate School of Medicine, Tohoku University, Sendai 980-8575, Japan

Dr. Hiroko Masuda

Department of Breast Surgical Oncology, School of Medicine, Showa University, Tokyo 142-8666, Japan

## Deadline for manuscript submissions

31 August 2025



## Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/228145

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





## **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

#### Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

### **Author Benefits**

## **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

